BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 37061677)

  • 1. Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients.
    Schneider J; Wobser R; Kühn W; Wagner D; Tanriver Y; Walz G
    BMC Nephrol; 2023 Apr; 24(1):99. PubMed ID: 37061677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nirmatrelvir/ritonavir Use With Tacrolimus in Lung Transplant Recipients: A Single-center Case Series.
    Dewey KW; Yen B; Lazo J; Seijo L; Jariwala R; Shah RJ; Quan D; Carpenter B; Paul Singer J; Breen K; Hays S; Florez R
    Transplantation; 2023 May; 107(5):1200-1205. PubMed ID: 36525555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Saving lives with nirmatrelvir/ritonavir one transplant patient at a time".
    Belden KA; Yeager S; Schulte J; Cantarin MPM; Moss S; Royer T; Coppock D
    Transpl Infect Dis; 2023 Apr; 25(2):e14037. PubMed ID: 36847419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nirmatrelvir/ritonavir-induced elevation of blood tacrolimus levels in a patient in the maintenance phase post liver transplantation.
    Shiohira H; Arakaki S; Uehara W; Uehara H; Yamamoto K; Nakamura K
    J Infect Chemother; 2024 Jan; 30(1):77-80. PubMed ID: 37689137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated tacrolimus levels after treatment with nirmatrelvir/ritonavir (Paxlovid) for COVID-19 infection in a child with a kidney transplant.
    Young C; Papiro T; Greenberg JH
    Pediatr Nephrol; 2023 Apr; 38(4):1387-1388. PubMed ID: 35982345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin.
    Sindelar M; McCabe D; Carroll E
    J Med Toxicol; 2023 Jan; 19(1):45-48. PubMed ID: 36536192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nirmatrelvir/ritonavir treatment of patients with COVID-19 taking tacrolimus: case series describing the results of drug-drug interactions.
    Shen D; Gong Y; Qian Y; Zhu J; Gao J
    J Int Med Res; 2024 May; 52(5):3000605241247705. PubMed ID: 38698526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19.
    Boland L; Devresse A; Monchaud C; Briol S; Belaiche S; Giguet B; Couzi L; Thaunat O; Esposito L; Meszaros M; Roussoulieres A; Haufroid V; Le Meur Y; Lemaitre F
    Transpl Int; 2024; 37():12360. PubMed ID: 38596505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case Report.
    Prikis M; Cameron A
    Transplant Proc; 2022; 54(6):1557-1560. PubMed ID: 35599203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenytoin enzyme induction for management of supratherapeutic tacrolimus levels due to drug-drug interaction with nirmatrelvir/ritonavir: Case series and discussion.
    Marsh J; Logan AT; Bilgili EP; Bowman LJ; Webb AR
    Am J Health Syst Pharm; 2024 Jun; 81(13):e345-e352. PubMed ID: 38347740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series.
    Guzmán Cordero C; Saez-Torres de Vicente M
    Eur J Hosp Pharm; 2024 Feb; 31(2):175-177. PubMed ID: 36535689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A model-based pharmacokinetic assessment of drug-drug interaction between tacrolimus and nirmatrelvir/ritonavir in a kidney transplant patient with COVID-19.
    Tomida T; Itohara K; Yamamoto K; Kimura T; Fujita K; Uda A; Kitahiro Y; Yokoyama N; Hyodo Y; Omura T; Yano I
    Drug Metab Pharmacokinet; 2023 Dec; 53():100529. PubMed ID: 37924724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-drug interactions of ritonavir-boosted SARS-CoV-2 protease inhibitors in solid organ transplant recipients: experience from the initial use of lopinavir-ritonavir.
    Gonzalez-García R; Roma JR; Rodríguez-García M; Arranz N; Ambrosioni J; Bodro M; Castel MÁ; Cofan F; Crespo G; Diekmann F; Farrero M; Forner A; LLigoña A; Marcos MÁ; Moreno A; Ruiz P; Soy D; Brunet M; Miró JM; Tuset M
    Clin Microbiol Infect; 2023 May; 29(5):655.e1-655.e4. PubMed ID: 36641051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case report of a prolonged decrease in tacrolimus clearance due to co-administration of nirmatrelvir/ritonavir in a lung transplant recipient receiving itraconazole prophylaxis.
    Tsuzawa A; Katada Y; Umemura K; Sugimoto M; Nishikawa A; Sato YK; Yoshida Y; Kitada N; Yonezawa A; Nakajima D; Date H; Terada T
    J Pharm Health Care Sci; 2023 Apr; 9(1):12. PubMed ID: 37004119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.
    Aggarwal NR; Molina KC; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Ginde AA
    Lancet Infect Dis; 2023 Jun; 23(6):696-705. PubMed ID: 36780912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing the use of nirmatrelvir/ritonavir in solid organ transplant recipients with COVID-19: A review of immunosuppressant adjustment strategies.
    Tang Y; Li Y; Song T
    Front Immunol; 2023; 14():1150341. PubMed ID: 37081880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case report of drug interaction between co-packaged nirmatrelvir-ritonavir and tacrolimus causing hyponatremia in a lung transplant recipient.
    Lo CM; Chen WH; Tsai MY; Lu HI; Hsiao YH; Chuang KH; Chen Y; Wu HF; Huang KT; Wang YH
    J Cardiothorac Surg; 2024 Mar; 19(1):132. PubMed ID: 38491538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical discovery and development of nirmatrelvir/ritonavir combinational therapy for the treatment of COVID-19 and the lessons learned from SARS-COV-2 variants.
    Pagliano P; Spera A; Sellitto C; Scarpati G; Folliero V; Piazza O; Franci G; Conti V; Ascione T
    Expert Opin Drug Discov; 2023; 18(12):1301-1311. PubMed ID: 37614103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19.
    Lemaitre F; Budde K; Van Gelder T; Bergan S; Lawson R; Noceti O; Venkataramanan R; Elens L; Moes DJAR; Hesselink DA; Pawinski T; Johnson-Davis KL; De Winter BCM; Pattanaik S; Brunet M; Masuda S; Langman LJ
    Ther Drug Monit; 2023 Apr; 45(2):191-199. PubMed ID: 35944126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans.
    Eng H; Dantonio AL; Kadar EP; Obach RS; Di L; Lin J; Patel NC; Boras B; Walker GS; Novak JJ; Kimoto E; Singh RSP; Kalgutkar AS
    Drug Metab Dispos; 2022 May; 50(5):576-590. PubMed ID: 35153195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.